AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the Piper Jaffray Europe Conference in London on Wednesday, June 24, 2009 at 10:30 a.m. British Summer Time/ 5:30 a.m. ET. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview. The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com/. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. About Amylin Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Michael York, Senior Director, Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602 Web Site: http://www.amylin.com/

Copyright